The EPAC–Rap1 pathway prevents and reverses cytokine-induced retinal vascular permeability

• Published in: The Journal of biological chemistry 2018-01, Vol.293 (2), p.717-730
• Main Authors: Ramos, Carla J., Lin, Chengmao, Liu, Xuwen, Antonetti, David A.
• Format: Article
• Language: English
• Subjects: Acetylcysteine - analogs & derivatives; Acetylcysteine - metabolism; Animals; blood–retinal barrier; Capillary Permeability - drug effects; Cell Biology; Cytokines - pharmacology; EPAC; Erythromycin - analogs & derivatives; Erythromycin - metabolism; Humans; rap1 GTP-Binding Proteins - metabolism; Ras-related protein 1 (Rap1); Receptors, Vascular Endothelial Growth Factor - metabolism; Retina - drug effects; Retina - metabolism; Signal Transduction - drug effects; small GTPase; tight junction; tumor necrosis factor (TNF); vascular endothelial growth factor (VEGF)
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.M117.815381

Increased retinal vascular permeability contributes to macular edema, a leading cause of vision loss in eye pathologies such as diabetic retinopathy, age-related macular degeneration, and central retinal vein occlusions. Pathological changes in vascular permeability are driven by growth factors such as VEGF and pro-inflammatory cytokines such as TNF-α. Identifying the pro-barrier mechanisms that block vascular permeability and restore the blood–retinal barrier (BRB) may lead to new therapies. The cAMP-dependent guanine nucleotide exchange factor (EPAC) exchange-protein directly activated by cAMP promotes exchange of GTP in the small GTPase Rap1. Rap1 enhances barrier properties in human umbilical endothelial cells by promoting adherens junction assembly. We hypothesized that the EPAC–Rap1 signaling pathway may regulate the tight junction complex of the BRB and may restore barrier properties after cytokine-induced permeability. Here, we show that stimulating EPAC or Rap1 activation can prevent or reverse VEGF- or TNF-α–induced permeability in cell culture and in vivo. Moreover, EPAC activation inhibited VEGF receptor (VEGFR) signaling through the Ras/MEK/ERK pathway. We also found that Rap1B knockdown or an EPAC antagonist increases endothelial permeability and that VEGF has no additive effect, suggesting a common pathway. Furthermore, GTP-bound Rap1 promoted tight junction assembly, and loss of Rap1B led to loss of junctional border organization. Collectively, our results indicate that the EPAC–Rap1 pathway helps maintain basal barrier properties in the retinal vascular endothelium and activation of the EPAC–Rap1 pathway may therefore represent a potential therapeutic strategy to restore the BRB.